Xospata (gilteritinib) treats adults with acute myeloid leukemia (AML) that has a specific FLT3 mutation. This medication is approved for people who’ve tried other treatments before to treat their leukemia. Xospata (gilteritinib) is a targeted cancer medication that’s taken by mouth once daily, but you have to take 3 tablets each time for a full dose. Side effects can include muscle pain, tiredness, and a serious condition called differentiation syndrome.
Advanced acute myeloid leukemia (AML) with an FTL3 mutation; previously treated
Some people with AML have a mutation in a protein called FLT3. This protein is found on stem cells and it normally sends signals to the cells to divide and spread. Having an FLT3 mutation causes the cells to grow uncontrollably, leading to leukemia.
Xospata (gilteritinib) is a tyrosine kinase inhibitor known as an FLT3 inhibitor. It blocks the mutated FLT3 protein from sending signals to cancer cells to grow. When these signals are blocked, the leukemia cells can’t grow and spread as well.
Source: DailyMed
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):
Is a tablet that’s taken by mouth
Works in a more specific, targeted way than traditional chemotherapy
Less likely to cause nausea
Commonly causes muscle pain and tiredness
Requires regular EKGs and blood work to check for side effects
Risk for a rare, but serious condition called differentiation syndrome
You can take Xospata (gilteritinib) with or without food. Swallow the tablets whole; don’t crush or chew them.
It’s important to go to your appointments for lab work whenever your oncologist tells you to. Xospata (gilteritinib) has a risk for side effects that are detected through your blood work. These can include pancreatitis, low white blood cells, and changes to your liver health. Your oncologist makes sure the medication is safe for you by checking your lab work.
Check your temperature often, preferably once a day. Call your healthcare team right away if you have a fever (a temperature of 100.4 degrees Fahrenheit or higher). Your care team will want to check your blood cell counts if you have a fever. This is because having a fever with very low white blood cell levels can be a side effect of Xospata (gilteritinib), and it can put you at risk for infection.
Tell your healthcare team about any new medications while you’re taking Xospata (gilteritinib). Some medications can interact with Xospata (gilteritinib). And these interactions can affect how well the medications work or affect your risk of side effects. Your healthcare team can make sure your medications are safe to take together.
If you or your partner can become pregnant and you’re sexually active, use birth control during your treatment with Xospata (gilteritinib). This medication can harm an unborn baby. Continue using birth control for 4 months (if you’re male) or for 6 months (if you’re female) after your last dose of Xospata (gilteritinib). Contact your healthcare team if you or your partner becomes pregnant during treatment.
Avoid breastfeeding while you’re taking Xospata (gilteritinib)] and for 2 more months after your last dose. We don’t know whether the medication gets into breast milk and whether it affects breastfed babies. But there’s a possible risk of harm to a baby.
Ask your oncologist about the best and safest way to handle and throw away Xospata (gilteritinib) when it expires or when your treatment ends. Anticancer medications can be harmful to people who handle or come in contact with them. Store the medication up and away, so children and pets can’t reach it.
Xospata (gilteritinib) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Rarely, people who took Xospata (gilteritinib) developed a serious condition called differentiation syndrome. It’s an immune reaction that causes too much inflammation throughout the body, leading to possibly life-threatening problems. In studies, cases of differentiation syndrome happened as early as a day and up to 3 months after the start of treatment.
Call 911 right away if you have symptoms of differentiation syndrome such as fever, trouble breathing, rapid weight gain, chest pain, and low blood pressure. Differentiation syndrome is a medical emergency so it’s important to get treated as soon as possible.
You’ll typically need treatment with corticosteroids, such as dexamethasone, and sometimes other medications to keep your blood pressure up. If your symptoms are severe or if they last for more than a few days, you might need to stop Xospata (gilteritinib) until they get better with treatment.
Some people who took Xospata (gilteritinib) developed a rare condition called posterior reversible encephalopathy syndrome (PRES). This condition affects the brain and can lead to symptoms such as vision changes, confusion, seizures, and sometimes loss of consciousness or coma. Get medical help right away if you have these symptoms so you can get examined. You’ll need to completely stop taking Xospata (gilteritinib) if you develop PRES.
Risk factors: History of abnormal heart rhythms | Taking other medications that can affect heart rhythm
It’s possible for Xospata (gilteritinib) to make the time it takes for your heart to relax after it contracts become longer. This is called QT prolongation and can lead to changes in heart rhythm. Seek medical help right away if you have sudden chest pain, feel very dizzy, or pass out.
Your oncologist will check for heart rhythm changes before you start Xospata (gilteritinib) and during treatment. You’ll need blood work done to check your electrolyte levels because this can affect your heart rhythm. You’ll also need to get a test called an electrocardiogram (EKG) to check the electrical activity of your heart. If you have heart rhythm changes on your EKG, your oncologist might pause your treatment and then restart the medication at a lower dose.
Though uncommon, some people who take Xospata (gilteritinib) can develop swelling in their pancreas, or pancreatitis. Contact a healthcare professional if you have stomach pain that might spread to your back, fever, nausea, or vomiting. These can be symptoms of pancreatitis. You might need to take a break from treatment while your care team looks into it. After your pancreas gets better, you might need to restart Xospata (gilteritinib) at a lower dose.
Risk factors: Pregnancy
Based on animal studies and the way the medication works, Xospata (gilteritinib) might harm an unborn baby or raise the risk for miscarriage (pregnancy loss) when it’s taken during pregnancy. Because of these risks, your oncologist might require you to have a negative pregnancy test before you start treatment.
It’s important to avoid becoming pregnant during your cancer treatment with Xospata (gilteritinib). If you’re a female who can get pregnant, use birth control while you’re taking this medication and for another 6 months after the last dose. And if you’re a male and your partner can get pregnant, you should use condoms while you’re taking Xospata (gilteritinib) and for 4 more months after the last dose. Contact your oncologist right away if you become pregnant while you’re taking Xospata (gilteritinib).
The typical dose is 120 mg by mouth once a day.
Advanced acute myeloid leukemia (AML) with an FTL3 mutation; previously treated
Acute myeloid leukemia (AML) with a specific mutation (FLT3-positive)
Acute myeloid leukemia (AML) with a FTL3 mutation
By signing up, I agree to GoodRx's Terms and Privacy Policy, and to receive marketing messages from GoodRx.
American Cancer Society. (2019). Chemotherapy safety.
American Cancer Society. (2021). How targeted therapies are used to treat cancer.
American Cancer Society. (2024). Neutropenia (low white blood cell counts).
American Cancer Society. (2024). Targeted therapy drugs for acute myeloid leukemia (AML).
Astellas Pharma Inc. (2018). Xospata® (gilteritinib) approved by U.S. FDA for adult patients and relapsed/refractory acute myeloid leukemia (AML) with a FLT3 mutation.
Astellas Pharma US, Inc. (2022). Xospata- gilteritinib tablet [package insert]. DailyMed.
Fathi, A. T., et al. (2021). Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia. American Journal of Hematology.
Kennedy, V. E., et al. (2020). FLT3 mutations in acute myeloid leukemia: Key concepts and emerging controversies. Frontiers in Oncology.
Leukemia & Lymphoma Society. (n.d.). Bone marrow tests.
National Cancer Institute. (n.d.). Leukemia–Patient version.
National Cancer Institute. (2024). Acute myeloid leukemia treatment (PDQ®) – Patient version.
National Center for Complementary and Integrative Health. (2020). St. John’s wort.
National Comprehensive Cancer Network. (2021). Anemia and neutropenia: Low red and white blood cell counts.
National Comprehensive Cancer Network. (2024). Acute myeloid leukemia.
National Institute of Diabetes and Digestive and Kidney Diseases. (2017). Symptoms & causes of pancreatitis.
National Institutes of Health. (n.d.). Stem cell basics.
Olivero, J. J., Sr. (2016). Cardiac consequences of electrolyte imbalance. Methodist DeBakey Cardiovascular Journal.
Patel, K., et al. (2017). Febrile neutropenia. JAMA Oncology.
Triplett, J. D., et al. (2022). Posterior reversible encephalopathy syndrome (PRES): Diagnosis and management. Practical Neurology.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.